Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Sirolimus

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sirolimus, Rapamune,Rapamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 114,640Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Fast-Tracks Palvella's QTORIN for Angiokeratomas
    FDA Fast-Tracks Palvella's QTORIN for Angiokeratomas

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206115/0/en/Palvella-Therapeutics-Granted-FDA-Fast-Track-Designation-for-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Angiokeratomas.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Sarepta to Test Elevidys with Immunosuppressive Regimen
    Sarepta to Test Elevidys with Immunosuppressive Regimen

    26 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125916203/en/Sarepta-Announces-Approval-to-Begin-ENDEAVOR-Cohort-8-to-Evaluate-Enhanced-Immunosuppression-Regimen-as-Part-of-ELEVIDYS-Gene-Therapy-for-Non-Ambulant-Individuals-with-Duchenne

    BUSINESSWIRE
    26 Nov 2025
    Share Share
    Quoin Hits Target Loadings For Two Topical Rapamycin Platforms
    Quoin Hits Target Loadings For Two Topical Rapamycin Platforms

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Orchestra BioMed Enrolls First Patients in Virtue SAB US Trial
    Orchestra BioMed Enrolls First Patients in Virtue SAB US Trial

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174623/0/en/Orchestra-BioMed-Announces-First-Patients-Enrolled-in-Virtue-SAB-US-Pivotal-IDE-Coronary-Trial.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Fda Awards Year Two Grant for Palvella's Qtorin Phase 3 Trial
    Fda Awards Year Two Grant for Palvella's Qtorin Phase 3 Trial

    13 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/13/3165451/0/en/U-S-Food-and-Drug-Administration-Awards-Year-Two-Proceeds-from-Orphan-Products-Grant-Supporting-Palvella-Therapeutics-Phase-3-SELVA-Trial-of-QTORIN-Rapamycin-for-Microcystic-Lympha.html

    GLOBENEWSWIRE
    13 Oct 2025
    Share Share
    Spur Elute Deeper Coronary Study Completes Enrollment
    Spur Elute Deeper Coronary Study Completes Enrollment

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250929471329/en/Spur-Elute-DEEPER-CORONARY-Study-Completes-Enrollment

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.